PTG-100: An Oral a4b7 Integrin Peptide Antagonist For Treatment Of Ulcerative Colitis

Ashok Bhandari

Senior Director, Chemistry, Protagonist Therapeutics

COMPANY DESCRIPTION

This presentation will describe
•Protagonist’s peptide technology platform for de novo discovery of peptides against protein protein interaction (PPI) targets
•Discovery & development candidate nomination of PTG-100 as an oral, GI (gastro-intestinal) restricted oral α4β7 integrin peptide antagonist
•In vitro, in vivo and pre-clinical profiling of PTG-100